OYST Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Benzinga - Mentions: UNP KMPR AAPL SNAP ...

Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7

3 years ago - By: InvestorPlace - Mentions: DIS AAPL DVN VTRS ...

The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year

3 years ago - By: InvestorPlace - Mentions: BIIB BNTX PFE INCY ...

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

3 years ago - By: The Motley Fool - Mentions: VTRS

Why Viatris Stock Is Jumping Today

3 years ago - By: Benzinga - Mentions: VTRS

Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge

3 years ago - By: InvestorPlace - Mentions: VTRS

Viatris (VTRS) Stock Pops 17% on Acquisition News

3 years ago - By: Kahn Swick & Foti, LLC

OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

3 years ago - By: Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 years ago - By: The Motley Fool - Mentions: ABBV PFE ABT VTRS

Better Dividend Stock: AbbVie or Viatris?

3 years ago - By: Seeking Alpha

Oyster Point Pharma GAAP EPS of -$1.37 misses by $0.11, revenue of $5.59M misses by $8.72M (NASDAQ:OYST)

3 years ago - By: Oyster Point Pharma, Inc.

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

3 years ago - By: Kahn Swick & Foti, LLC

OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

3 years ago - By: Weiss Law - Mentions: VTRS

SHAREHOLDER ALERT: Weiss Law Investigates Oyster Point Pharma, Inc.

3 years ago - By: Ademi LLP

Shareholder Alert: Ademi LLP investigates whether Oyster Point Pharma, Inc. has obtained a Fair Price in its transaction with Viatris

3 years ago - By: Halper Sadeh LLC

OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders

3 years ago - By: Oyster Point Pharma, Inc.

OYSTER POINT PHARMA INC (OYST) Stock News

OYST Latest News, Press Relases and Analysis

Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7

The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond

Why Viatris Stock Is Jumping Today

Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge

Viatris (VTRS) Stock Pops 17% on Acquisition News

OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Better Dividend Stock: AbbVie or Viatris?

Oyster Point Pharma GAAP EPS of -$1.37 misses by $0.11, revenue of $5.59M misses by $8.72M (NASDAQ:OYST)

Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights

OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST

SHAREHOLDER ALERT: Weiss Law Investigates Oyster Point Pharma, Inc.

Shareholder Alert: Ademi LLP investigates whether Oyster Point Pharma, Inc. has obtained a Fair Price in its transaction with Viatris

OYST Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Oyster Point Pharma, Inc. Is Fair to Shareholders

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris